Diagnostic Investors Panel

This 50-minute panel focuses on investments in innovative diagnostics, ranging from IVD, genomics, precision medicine, and more. Topics may include:

• Current areas of interest
• Current challenges in this ecosystem
• Navigating the competitive landscape
• Commonly observed red flags
• Successful deals

Panelists will discuss how companies can successfully fundraise for their budding diagnostics technology and the best way to successfully approach and develop a relationship with relevant investors. Panelists will also explore current areas of interest and why they are relevant, as well as developmental and regulatory hurdles and how companies can address these problems to attain key milestones.

• Nola Masterson, Managing Director, Science Futures

Nola Masterson is a lead investor in Porfolia FemTech Fund. The fund invests in woman’s healthcare issues which utilize tech. She is the co-founder of Sequenom, Inc. She has a background in sales and marketing from Ames Company (Bayer) and Millipore. She was the first biotech analyst in biotechnology at Drexel and Merrill Lynch. She has worked with venture capital firms such as KPCB and Oak Investments. She has raised her own VC fund in the late 90’s. She was a venture partner with TechnoVenture Management and opened their San Francisco office. She is the co-chair of the Woman Corporate Director San Francisco Chapter and sits on the board of several startup companies and is on the public board of Zivo BioSciences Inc.

• Diana Saraceni, Founder & Managing Partner, Panakes Partners

Diana Saraceni is an investor with long experience in Venture Capital. She is currently Co-Founder & General Partner at Panakes Partners (www.panakes.it), an Italian Venture Capital firm dedicated to early stage investments in healthcare in Europe and Israel. Diana can rely on over 15 years of Venture Capital experience. She has also co-founded and managed 360 Capital Partners (www.360capitalpartners.com), one of the leading Venture Capital firm in Europe. She has led investments in a significant number of companies all over Europe, not only in the medical device sector, and generated several exits as IPO and M&A transactions. Ms Saraceni has a strong knowledge of the Venture Capital community in Italy and Europe. Ms. Saraceni holds an Msc in Engineering and an MBA from Luiss University.

• Erik Lium, Executive Vice President, Mount Sinai Innovation Partners

Dr. Lium joined the Mount Sinai Health System as Vice President of Mount Sinai Innovation Partners (MSIP) in 2014 and was named Executive Vice President in 2018. Earlier in his career, Dr. Lium held positions at the University of California, San Francisco (UCSF), including Assistant Vice Chancellor of Innovation, Technology and Alliances; Principal Investigator for the Bay Area National Science Foundation I-Corps node; and Assistant Vice Chancellor of Research. He also served as Founder and President of LabVelocity Inc., an information services company focused on accelerating research and development in the life sciences. He routinely advises venture boards, and serves on the board of several startups launched from Mount Sinai technology. Dr. Lium earned his PhD in Cellular, Molecular and Biophysical Studies at Columbia University and pursued post-doctoral training at UCSF.

• Noel Jee, Senior Associate, Illumina Ventures

Noel joined Illumina Ventures in 2017 and focuses on investments in biopharma, life science tools, and diagnostics. Prior to joining Illumina Ventures, Noel was a management consultant at L.E.K. Consulting where he developed strategic business insights for biopharma and diagnostics companies. At L.E.K. Consulting, he developed commercial launch strategies for new therapeutics, engaged in diligence efforts for asset acquisitions, created portfolio expansion strategies for biopharma, and shaped organizational restructuring efforts for clients across the life science sector. ​ As an avid enthusiast of the entrepreneurial ecosystem, Noel helped bootstrap an asthma-focused diagnostics startup during graduate school, created and ran an IT startup in college, and played an active role in the startup communities at both universities. Noel obtained his Ph.D. in Chemistry and Chemical Biology from the University of California, San Francisco, and a dual B.S. in Biochemistry and Physiology and Neurobiology from the University of Maryland, College Park.

• Ted Driscoll, Managing Partner, DigitalDx Ventures

Dr. Ted Driscoll is Managing Partner at DigitalDx Ventures, focused on early detection of health issues and what to do about them. Previously he was partner at Claremont Creek Ventures, leading Digital Healthcare, where he led early investments in Natera, AssureX, GeneWeave, Numedii, Prime Genomics, Gigagen, DNAnexus, Tibion, Cureus, and Zipline. They were all successful. Prior to venture experience, Ted helped found five successful companies in imaging-related markets. He was founder of Be Here Technologies, a pioneer in 360deg imaging, that was sold to Google and became StreetView. At Diasonics, he led the team that commercialized the first MRI scanners. Previously, he was VP of Engineering at Identix, where he wrote the first code for digital fingerprint recognition. Ted was mayor of Portola Valley for five terms and on the council for 20 years, and he holds a Stanford PhD, two Harvard Masters and a Penn Bachelors

Go Back to Agenda